Literature DB >> 3918846

The effects of thyroid hormone deprivation in vivo and in vitro on growth hormone (GH) responses to human pancreatic (tumor) GH-releasing factor (1-40) by dispersed rat anterior pituitary cells.

C Dieguez, S M Foord, J R Peters, R Hall, M F Scanlon.   

Abstract

Anterior pituitary cells from euthyroid and hypothyroid male rats have been cultured as monolayers for 3 days with or without 5 nM T3 and stimulated with either human pancreatic GH-releasing factor 1-40 (hpGRF), TRH, or the Ca2+ channel ionophore A23187. Basal GH secretion was reduced in the hypothyroid cultures (P less than 0.001) and basal TSH secretion increased (P less than 0.001). Culture with T3 increased GH secretion and intracellular GH content in euthyroid and hypothyroid cultures but suppressed TSH secretion with no effect on intracellular TSH content in either euthyroid or hypothyroid cultures. hpGRF released more GH from euthyroid [3.52 +/- 0.2 (SE) micrograms/6 h X 10(5) cells] than hypothyroid cultures of (0.17 +/- 0.01 micrograms/6 h X 10(5) cells, P less than 0.001) without a change in ED50 (approximately 0.02 nM). The reduction in hpGRF-induced GH release remained significant when corrected for the reduced intracellular GH content in the hypothyroid cultures. hpGRF-induced GH release also declined relative to A23187-induced GH release in hypothyroid cultures. Culture with 5 nM T3 doubled maximum hpGRF-induced GH release in euthyroid cultures and increased maximum release 10-fold in hypothyroid cultures without altering the ED50 of hpGRF action. In contrast, T3 suppressed TRH-induced TSH release in euthyroid cultures but was without effect on TRH-induced TSH release in the hypothyroid cultures. T3 did not effect the ED50 of TRH action (2-5 nM). In summary, hypothyroid rat anterior pituitary cells in culture have a reduced maximal GH response to hpGRF, but the same ED50. hpGRF activity can be partially restored by physiological concentrations of T3 in vitro.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3918846     DOI: 10.1210/endo-116-3-1066

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Acute decrease in circulating T3 levels enhances, but does not normalise, the GH response to GHRP-6 plus GHRH in thyrotoxicosis.

Authors:  S O Nascif; M H Senger; J C Ramos-Dias; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

Review 2.  Thyroid hormones and growth hormone secretion.

Authors:  R Valcavi; M Zini; I Portioli
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

3.  Role of growth hormone-releasing hormone on pentagastrin-induced growth hormone release in normal subjects.

Authors:  J F Garcia-Rojas; A Mangas; A Barba; J Millan; C Dieguez; E Zamora
Journal:  J Endocrinol Invest       Date:  1991-03       Impact factor: 4.256

4.  Thyroid hormone modulation of the hypothalamic growth hormone (GH)-releasing factor-pituitary GH axis in the rat.

Authors:  N Miki; M Ono; N Hizuka; T Aoki; H Demura
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

5.  Cis-unsaturated free fatty acids block VIP-mediated GH and PRL secretion by perturbing the cAMP/protein kinase A pathway.

Authors:  F R Pérez; J P Camiña; C Menéndez; A Beiras; X Casabiell; F F Casanueva
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

6.  Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.

Authors:  Sergio Oliva Nascif; Silvia Regina Correa-Silva; Marcos Roberto Silva; Ana-Maria Judith Lengyel
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

7.  Decreased hypothalamic growth hormone-releasing hormone content and pituitary responsiveness in hypothyroidism.

Authors:  H Katakami; T R Downs; L A Frohman
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.